MediCor looks to sell substantially all assets for $51.5 million

By Caroline Salls

Pittsburgh, March 25 - MediCor Ltd. requested court approval of the sale of substantially all of its assets through a series of transactions, according to a Monday filing with the U.S. Bankruptcy Court for the District of Delaware.

Specifically, Global Consolidated Aesthetics (US) Corp. has agreed to buy the company's pre-market approval application-related assets for $1.5 million; Global Consolidated Aesthetics France SAS has agreed to buy all 33,750 of MediCor subsidiary ES Holdings SAS' Eurosilicone SAS shares for $38 million; Global Consolidated Aesthetics UK Ltd. has agreed to buy Biosil UK Ltd.'s Biosil Ltd. outstanding shares for $5 million; and Global Consolidated Holdings Ltd. will buy Biosil UK's Nagor Ltd. shares for $7 million.

Global Consolidated has paid a $5.15 million deposit toward the total purchase price.

As previously reported, MediCor attempted to sell substantially all of its assets in 2007, but it was forced to withdraw that sale motion when it received no qualified bids.

Because of its previous lack of qualified bids and its extensive marketing process, the company said it will not solicit competing bids under this sale attempt.

A hearing is scheduled for April 9.

MediCor, a North Las Vegas, Nev., health care company that makes and sells products for the aesthetic, plastic and reconstructive surgery and dermatology markets, filed for bankruptcy on June 29, 2007. Its Chapter 11 case number is 07-10877.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.